Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
IGC Pharma Inc (AMEX: IGC) closed the day trading at $0.36 down -2.73% from the previous closing price of $0.37. In other words, the price has decreased by -$2.73 from its previous closing price. On the day, 0.46 million shares were traded. IGC stock price reached its highest trading level at $0.375 during the session, while it also had its lowest trading level at $0.3515.
Ratios:
For a better understanding of IGC, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.46 and its Current Ratio is at 1.25. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IGC now has a Market Capitalization of 32737444 and an Enterprise Value of 32076044. For the stock, the TTM Price-to-Sale (P/S) ratio is 24.62 while its Price-to-Book (P/B) ratio in mrq is 4.93. Its current Enterprise Value per Revenue stands at 24.172 whereas that against EBITDA is -5.027.
Stock Price History:
The Beta on a monthly basis for IGC is 0.24, which has changed by 0.058823586 over the last 52 weeks, in comparison to a change of 0.1476624 over the same period for the S&P500. Over the past 52 weeks, IGC has reached a high of $0.50, while it has fallen to a 52-week low of $0.25. The 50-Day Moving Average of the stock is -11.52%, while the 200-Day Moving Average is calculated to be 3.93%.
Shares Statistics:
Over the past 3-months, IGC traded about 980.23K shares per day on average, while over the past 10 days, IGC traded about 892260 shares per day. A total of 84.14M shares are outstanding, with a floating share count of 70.60M. Insiders hold about 26.80% of the company’s shares, while institutions hold 4.12% stake in the company. Shares short for IGC as of 1761868800 were 284005 with a Short Ratio of 0.29, compared to 1759190400 on 328584. Therefore, it implies a Short% of Shares Outstanding of 284005 and a Short% of Float of 0.41000000000000003.
Earnings Estimates
. The current assessment of IGC Pharma Inc (IGC) involves the perspectives of 2.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.02, with high estimates of -$0.02 and low estimates of -$0.02.
Analysts are recommending an EPS of between -$0.08 and -$0.08 for the fiscal current year, implying an average EPS of -$0.08. EPS for the following year is -$0.09, with 2.0 analysts recommending between -$0.08 and -$0.09.
Revenue Estimates
2 analysts predict $383k in revenue for. The current quarter. It ranges from a high estimate of $441k to a low estimate of $325k. As of. The current estimate, IGC Pharma Inc’s year-ago sales were $412kFor the next quarter, 2 analysts are estimating revenue of $316.5k. There is a high estimate of $325k for the next quarter, whereas the lowest estimate is $308k.
A total of 2 analysts have provided revenue estimates for IGC’s current fiscal year. The highest revenue estimate was $1.5M, while the lowest revenue estimate was $1.3M, resulting in an average revenue estimate of $1.4M. In the same quarter a year ago, actual revenue was $1.27MBased on 2 analysts’ estimates, the company’s revenue will be $1.57M in the next fiscal year. The high estimate is $1.65M and the low estimate is $1.5M.
